Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. News
  7. Summary
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica International : Capital Markets Day invitation June 9

05/22/2021 | 08:31am EDT

Biovica, active in cancer diagnostics, will host a virtual Capital Markets Day on Wednesday 9 June from 14.00 to 16.30.

Biovica is approaching market launch of DiviTum®TKa in the US for the monitoring of metastatic breast cancer treatments. Today, DiviTum®TKa is sold for research purposes primarily to major pharmaceutical companies for use in clinical studies. Following FDA approval expected in 2021, the large market for patient monitoring will be available.

We therefore invite you to a virtual Capital Markets Day on June 9, 2021 at 14.00 to 16.30.
https://tv.streamfabriken.com/biovica-international-virtual-capital-markets-day-2021

Questions can be sent in advance or during the event to ir@biovica.com

At the Capital Markets Day, among others, Luca Malorni, MD, PhD, will participate to give his view on DiviTum®TKa. Dr. Malorni is a medical oncologist and Director of the Translational Research Unit of the Hospital of Prato and principal investigator in several studies with DiviTum®TKa.

Welcome!

© Modular Finance, source Nordic Press Releases

All news about BIOVICA INTERNATIONAL AB (PUBL)
09/15BIOVICA INTERNATIONAL : DiviTum«TKa results from SWOG study published in Clinical Cancer R..
AQ
09/15Biovica Announces DiviTum«TKa results from SWOG study published in Clinical Cancer Rese..
CI
09/14BIOVICA INTERNATIONAL : Promising DiviTumTKa results from BioItaLEE study presented at ESM..
AQ
09/13BIOVICA INTERNATIONA : Biovica International
AQ
09/13BIOVICA INTERNATIONAL : provides update on FDA application process
AQ
09/13Biovica International AB Provides Update on FDA Application Process
CI
08/31BIOVICA INTERNATIONAL : Announcement from Biovica International's annual general meeting
AQ
08/31BIOVICA INTERNATIONAL : DiviTum«TKa approaching FDA approval
AQ
08/27BIOVICA INTERNATIONAL : CEO's presentation ahead of the 2021 Annual General Meeting has be..
AQ
08/10BIOVICA INTERNATIONAL : strengthens management team
AQ
More news
Financials
Sales 2022 48,6 M 5,61 M 5,61 M
Net income 2022 -32,6 M -3,76 M -3,76 M
Net cash 2022 252 M 29,1 M 29,1 M
P/E ratio 2022 -52,5x
Yield 2022 -
Capitalization 1 506 M 173 M 174 M
EV / Sales 2022 25,8x
EV / Sales 2023 8,26x
Nbr of Employees 20
Free-Float 41,9%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 53,00 SEK
Average target price 103,00 SEK
Spread / Average Target 94,3%
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Lars Erik Holmqvist Chairman
Mattias Bergqvist Director-Clinical Development
Otti Bengtsson Gref Director-Research & Development
Sector and Competitors